Category: Company
Quick infos Trade prices Volume: Market Cap: 122.37M Prev closed: Open: 4.56 High: 4.57 Low: 4.34 52 week low: 3.43 52 week high: 20.42 Dividends: No Dividends Next ER: March 8, 2023 After Market Closes
About the Company Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris and New York City.
Earnings History Date EPS / Forecast Revenue / Forecast May 10, 2023 March 8, 2023 -0.02 / -0.617.32M / 18.58MNovember 15, 2022 - / -0.4333- / 33.8MNovember 3, 2022 -0.63 / -0.44631.92M / 16.88MAugust 4, 2022 -0.42 / -0.51442.77M / 23.46Mview more
Historical Data Date Price Open High Low Vol Change ER Aug 4, 2022 3.12 3.15 3.38
3.02
151.33K -6.02% Aug 3, 2022 3.32 3.11 3.39
3.11
205.22K 7.79% Aug 2, 2022 3.08 2.94 3.08
2.90
274.40K 2.67% Aug 1, 2022 3.00 2.75 3.28
2.74
354.52K 14.50% Jul 29, 2022 2.62 2.75 2.75
2.57
86.83K -1.87% Jul 28, 2022 2.67 2.75 2.76
2.59
46.85K -4.3% Jul 27, 2022 2.79 2.70 2.79
2.66
47.55K 7.31% Jul 26, 2022 2.60 2.60 2.73
2.57
88.86K -2.26% Jul 25, 2022 2.66 2.71 2.72
2.62
24.20K -1.12% Jul 22, 2022 2.69 2.75 2.80
2.68
50.41K -1.47% view more
NASDAQ - Nasdaq Stock Market
More profiles and info about the company Founded:1999 Employees:122 News
Calyxt, Inc., Cellectis Majority-Owned Subsidiary, Reports Its First Quarter 2022 Financial Results finance.yahoo.com May 19, 2022 4:14 pm
Cellectis Presents Research Data on a Novel Immune-Evasive Universal CAR T-cell at ASGCT finance.yahoo.com May 16, 2022 8:15 am
Monthly information on share capital and company voting rights finance.yahoo.com May 10, 2022 4:43 pm
Natural Killer Cell Therapy Focused-Cytovia Turns To SPAC Merger For Public Market Debut finance.yahoo.com Apr 27, 2022 12:51 pm For Microsoft's Morrisville expansion, March 1 is important date bizjournals.com Apr 9, 2022 2:56 pm
Allogene (ALLO) Clinical Hold on CAR-T Studies Removed by FDA finance.yahoo.com Apr 9, 2022 11:11 am
Iovance (IOVA) Announces Wider-Than-Anticipated Q4 Loss finance.yahoo.com Apr 9, 2022 9:59 am
Cellectis Presents Preclinical Data from its First Allogeneic Dual CAR T-cell Product Candidate UCART20x22 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma at the American Association for Cancer Research (AACR) 2022 Annual Meeting finance.yahoo.com Apr 8, 2022 4:30 pm Cellectis rides on FDA’s Fast Track tag for Allogene’s CAR-T therapy seekingalpha.com Mar 11, 2022 11:31 pm Why Cellectis Stock Rose 20.7% This Week fool.com Mar 10, 2022 9:40 pm Cellectis GAAP EPS of -$0.18, revenue of $1.94M seekingalpha.com Mar 4, 2022 5:06 am Cellectis Q4 2021 Earnings Preview seekingalpha.com Mar 3, 2022 6:35 am Cellectis SA (CLLS) Q3 2021 Earnings Call Transcript fool.com Nov 5, 2021 5:00 pm
Monthly information on share capital and company voting rights finance.yahoo.com Apr 7, 2022 4:30 pm
Allogene (ALLO) Focuses on Pipeline Amid Lack of Marketed Drugs finance.yahoo.com Mar 18, 2022 9:15 am
Iovance Biotherapeutics Investigational New Drug Application (IND) Allowed to Proceed for TALEN®-Edited Tumor Infiltrating Lymphocyte (TIL) in Unresectable or Metastatic Melanoma and Stage III or IV Non-Small Cell Lung Cancer (NSCLC) finance.yahoo.com Mar 15, 2022 4:01 pm
Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2021 Financial Results finance.yahoo.com Mar 3, 2022 4:45 pm Cellectis ropes in biotech veteran Bing Wang as CFO seekingalpha.com Feb 11, 2022 5:55 am
Cellectis Appoints Bing Wang, PhD, MBA as Chief Financial Officer finance.yahoo.com Feb 10, 2022 4:30 pm
Henry James International Management Inc. ... finance.yahoo.com Jan 18, 2022 1:38 pm This company doesn't provide a dividend.
Key Persons CEO : André Choulika, PhD Talk about Cellectis SA below in comments section below. Do you think you'll buy? Do you already have active trades now?
EarningsAhead is not affiliated with and this is not an endorsement of the companies featured above. This profile is based on publicly available information and is intended to be informative in nature. Most of the datas are collected by our Data Entry and we aim to be as accurate as humanly possible.
Share it with fellow traders:
or join discussions in FB below
(
FB comments )
If you are looking for News & events, Press Release, they are available on their Investors Relations site.
Consensus BUY 80 HOLD 20 SELL 0
If you want to help pay for server cost or for improving this tool. You can send it via Paypal . More features coming soon :)
Buy on Amazon While many books explain the how of bitcoin, The Internet of Money delves into the why of bitcoin. Acclaimed information-security expert and author of Mastering Bitcoin, Andreas M. Antonopoulos examines and contextualizes the significance of bitcoin through a series of essays spanning the exhilarating maturation of this technology.